Clinical trial protocols: Agreements between the FDA and industrial sponsors

Lancet

Volumn 360, Issue 9343, 2002, Pages 1345-1346

  Mann, Howard ^a  

^a UNIVERSITY OF UTAH SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

PLACEBO;

CLINICAL PROTOCOL; CLINICAL RESEARCH; CLINICAL TRIAL; DRUG EFFICACY; DRUG INDUSTRY; DRUG RESEARCH; EXPERIMENTAL DESIGN; FOOD AND DRUG ADMINISTRATION; HUMAN; INFORMED CONSENT; MEDICAL ETHICS; MEDICAL LITERATURE; NOTE; OUTCOMES RESEARCH; PATIENT CARE; PATIENT SELECTION; PEER REVIEW; POLICY; PRESCRIPTION; PRIORITY JOURNAL; PUBLICATION; RANDOMIZATION; RISK BENEFIT ANALYSIS; SAFETY; SAMPLE SIZE; SCIENCE; VALIDATION PROCESS; WELFARE;

EID: 0037010409     PISSN: 01406736     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0140-6736(02)11415-2     Document Type: Note

References (12)

1. Moher D., Schulz K.F., Altman D.G. The CONSORT statement: revised recommendations for improving the quality of reports of parallel-group randomised trials. Lancet. 357:2001;1191-1194.
2. Emanuel E., Wendler D., Grady C. What makes clinical research ethical? JAMA. 283:2000;2701-2711.
3. Sackett D.L. Why randomized controlled trials fail but needn't; 2. Can Med Assoc J. 156:2001;1226-1237.
4. Freedman B. Equipoise and the ethics of clinical research. N Engl J Med. 317:1987;141-145.
5. Djulbegovic B. Acknowledgment about uncertainty: a fundamental means to ensure scientific and ethical validity in research. Curr Oncol Rep. 3:2001;389-395.
6. Freedman B. Multicenter trials and subject eligibility: should local IRBs play a role? IRB Rev Human Subjects Res. 16:1994;1-6.
7. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry E 10: Choice of Control Group and Related Issues in Clinical Trials. 2001: http://www.fda.gov/cder/guidance/4155fnl.htm (accessed Aug 27, 2002).
8. US Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Special Protocol Assessment. 2002: http://www.fda.gov/cder/guidance/3764fnl.htm (accessed Aug 27, 2002).
9. US Food and Drug Administration, Center for Devices and Radiological Health. Code of Federal Regulations Title 21: Food and Drugs. 2002: http://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfcfr/ showCFR.cfm?CFRPart=56 (accessed Aug 27, 2002).
10. US Food and Drug Administration. Information sheets: guidance for institutional review boards and clinical investigators. 1998: http://www.fda.gov/oc/ohrt/irbs/default.htm (accessed Aug 27, 2002).
11. Anonymous. Availability for public disclosure and submission to FDA for public disclosure of certain data and information related to human gene therapy or xenotransplantation. US Fed Reg 2001; 66: 4688-706.
12. Godlee F. Publishing trial protocols: Making them visible will improve registration, reporting and recruitment. BMC News Views 2001; 2: 4. http://www.biomedcentral.com/1471-8219/2/4/ (accessed Sept 9, 2002).